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Editorial
The hallmark of point-of-care testing is 
that the results can be obtained in a timely 
manner. This will enable clinicians to make 
decisions that are based on solid data and 
to perform course corrections during the 
treatment of the disease [1]. There are mul-
tiple point-of-care testing methods that are 
currently under development. Whereas vir-
tually any molecule (e.g., lipid spectrum) 
or macromolecule (e.g., proteins, DNA and 
RNA) of biological origin could be used as 
a biomarker, proteins are, to date, the most 
extensively studied candidates.
During the last decade, diagnostic lab-
oratories in academia and industry have 
been working on the development of a 
multitude of different approaches, among 
them electrochemical analysis methods [2], 
immunohistochemical staining methods 
[3], FISH [4], ELISA [5] and the many vari-
ants of PCR [6], such as reverse transcrip-
tion PCR (RT-PCR) [7] and quantitative 
or real-time PCR (qPCR) [8], as well as 
quantitative fluorescence detection/image 
analysis [9].
Virtually all of these methods have 
the potential to be miniaturized so that 
they can be used routinely in the phy-
sician’s office, an ambulance or in the 
field. PCR methods for the detection of 
leukemia and lymphomas are already in 
use [10]. Electrochemical and fluorescence 
detection methods are especially suited 
to miniaturization. We expect that they 
will be available as implants within one 
or two decades. This technology will help 
to address the apparent disparity in the 
quality of healthcare that exists in the 
USA (Great Plains areas vs the coastal 
areas) and even more so when comparing 
the developing and the developed world. 
However, some of these technologies 
(e.g., FISH, ELISA, genomics and prot-
eomics) will remain in high-throughput 
analytical laboratories for the foreseeable 
future because they require considerable 
 investments and highly trained personnel.
All of these approaches combined will 
lead to significant changes in the way that 
healthcare is provided: we will experience 
a shift from curative medicine to predic-
tive and highly personalized medicine. 
Physicians will be able to rely on frequent 
testing to provide the best care possible. At 
the same time, advances in computer net-
working will allow cancer patients to pur-
sue their lives with much more personal 
freedom than what is possible today.
What advantages would point-
of-care routine rapid screening 
provide in cancer diagnostics 
& treatment?
According to the National Cancer 
Institute, “Cancer is not just one dis-
ease but many diseases. There are more 
than 100 different types of cancer” [101]. 
We use statistical methods to describe 
the response of cancers to treatment and 
classify them according to the cell type 
of origin. The required course of action 
is usually determined by the stage of the 
disease. Whereas there are acceptable 
treatment options available for numerous 
cancers if detected in early stages, survival 
statistics are far less favorable for cancers 
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in late stages. One of the major obstacles in treating cancers is 
detecting the disease in the localized stage, where surgical excision 
is possible. However, since cancer usually does not show discern-
ible symptoms in early stages, blood tests for routine screening, 
for example during annual check-ups, would reveal cancer sig-
nificantly earlier than it is discovered today. We anticipate that 
this screening option will become available sometime during the 
next 5 years. We further anticipate that after the re-election of 
President Obama, the insurance industry will become interested 
in tests for early cancer diagnostics, because pre-existing condi-
tions will not be an impediment to obtaining or retaining health 
insurance after 2014, thus creating an economic incentive for 
early cancer detection.
Point-of-care routine rapid screening will also be most use-
ful for cancer patients during surgery and during the course of 
chemotherapy. One of the main problems in the surgical exci-
sion of operable tumors is the definition of the tumor bound-
ary. A non-negligible fraction of the mortality of breast cancer 
patients arises from metastases that remain in the body, because 
the boundary between tumor tissue and presumably healthy 
tissue cannot be clearly identified by means of state-of-the-art 
histology [11]. Rapid screening methods that could be performed 
during surgery would significantly improve the standard of care 
in cancer surgery.
Similarly, there is a need for rapid screening methods during 
chemotherapy. Whereas immunoassays (e.g., HER2) [12] and, 
increasingly, testing for genetic subtypes will be very useful in 
selecting the most promising course of action in chemotherapy, 
these methods are not capable of detecting whether the selected 
drugs are actually working. The evaluation of a chemotherapy’s 
success or failure is traditionally performed based on the compari-
son of tumor sizes before and after therapy. However, it is usually 
the metastases that kill the patient, not the primary tumor, and 
the former are not easily quantifiable using state-of-the art imaging 
procedures. Most importantly, this evaluation is performed much 
too late in the game, due to the severe collateral damages inflicted 
by virtually all chemotherapeutic drugs. Point-of-care routine rapid 
screening methods will have to be developed that are capable of 
measuring the ‘rate of killing’ tumor cells 24 h after chemother-
apy has begun. Assessing the rate of cell damage of noncancerous 
cells at the same time is of equal importance. This would permit 
the adjustment of the doses of chemotherapeutic drugs and/or to 
change the cocktail that is administered if necessary.
The fourth group of cancer patients who could benefit from 
routine rapid screening is patients in remission and patients who 
have entered a chronic phase of the disease due to chemotherapy 
blocking the progress of metastases [13]. It is of vital importance 
to recognize a recurring cancer as early as possible. Otherwise, 
there are practically no viable treatment options available, because 
recurrent cancer is often highly invasive and drug resistant.
How do we envision point-of-care routine rapid 
screening methods in 2025?
Cancer medicine will be highly personalized: testing of genetic 
subtypes will be routinely employed to predict whether chemo-
therapy and/or signaling pathway blockade should be used and 
what kind of therapy is most promising in treating the particu-
lar cancer. Epigenetics (DNA methylation and expression of 
miRNA) is one promising approach to determining whether 
chemotherapy actually works. Another approach would be 
monitoring the protease signature of the patient. There is a 
wealth of literature available that serine proteases (urokinase 
plasminogen activator), numerous matrix metalloproteinases 
and many cathepsins are overexpressed by solid tumors [14]. 
These enzymes can be measured in tissue and blood by using 
immunoassays [15] or fluorescence detection methods relying 
on protease-selective consensus sequences [16]. The latter have 
the significant advantage of being up to four orders of mag-
nitude more sensitive (~10-16 vs 10-12 M). Furthermore, many 
proteases are secreted as inactive zymogens, which are detected 
by immunoassays, but not by fluorescence detection methods, 
which only quantify protease activities. Epigenetics and pro-
tease monitoring are also most promising in the early detection 
of cancer and monitoring chronic cancer patients and patients 
in remission.
During the last decade, there has been considerable discussion 
about monitoring circulating tumor cells (CTCs) for the purpose 
of early cancer detection and prediction of treatment outcome [15]. 
Several methods for capturing CTCs from peripheral blood have 
been developed. Although we regard the discovery of CTCs as a 
milestone in cancer research that is shedding light on the mecha-
nisms of cancer progression, we are less enthusiastic with regard to 
the potential of CTCs as prognostic markers. First, CTCs repre-
sent only a very small fraction of normal cells in peripheral blood 
to be isolated and counted. Second, there is a paucity of tumor 
markers applicable for CTC screening, and third, CTCs exhibit 
considerable heterogeneity and plasticity with subpopulations that 
have lost epithelial features [17]. Metabolic markers, such as the 
levels of matrix metalloproteinase expression, are mandatory to 
avoid mischaracterizations. Third, we may look at a minor frac-
tion of the CTCs due to their favorable size and relative ease of 
identification via surface markers. What alternatives do we have 
to CTCs? Instead of counting and interrogating a very minor 
fraction of cells in peripheral blood, neutrophils and monocytes 
may provide a much better insight into the characterization of 
the tumor-bearing host cells. Some early tumors, for example 
gliomas, are capable of changing the type of neutrophils from 
N1 (active) to N2 (inactive) [18]. These two types can be distin-
guished by means of their morphology and by measuring their 
protease expression levels of MMP8 and MMP9 (N1) and argi-
nase (N2). This method would have the advantage of counting 
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and characterizing a major fraction of blood cells, leading to much 
smaller detection errors.
In conclusion, developing point-of-care routine rapid screen-
ing methods for cancer diagnostics and therapy holds great 
promise for individual patients and for the healthcare system 
as a whole. Advances in this field will be truly transformative, 
but they require synergy between public resources and private 
investments.
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